{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:40:03Z","timestamp":1770478803271,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,2,13]],"date-time":"2008-02-13T00:00:00Z","timestamp":1202860800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s11739-008-0099-1","type":"journal-article","created":{"date-parts":[[2008,2,12]],"date-time":"2008-02-12T11:53:51Z","timestamp":1202817231000},"page":"161-163","source":"Crossref","is-referenced-by-count":9,"title":["Acute tumor lysis syndrome after rituximab administration in Burkitt\u2019s lymphoma"],"prefix":"10.1007","volume":"3","author":[{"given":"Zaher K.","family":"Otrock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan A.","family":"Hatoum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad M.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,2,13]]},"reference":[{"issue":"1 Suppl 2","key":"99_CR1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","volume":"29","author":"DG Maloney","year":"2002","unstructured":"Maloney DG, Smith B, Rose A (2002) Rituximab: mechanism of action and resistance. Semin Oncol 29 (1 Suppl 2):2\u20139","journal-title":"Semin Oncol"},{"key":"99_CR2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.thj.6200133","volume":"2","author":"J Bienvenu","year":"2001","unstructured":"Bienvenu J, Chvetzoff R, Salles G, et al (2001) Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2:378\u2013384","journal-title":"Hematol J"},{"key":"99_CR3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1523-5394.1998.006003195.x","volume":"6","author":"SD Scott","year":"1998","unstructured":"Scott SD (1998) Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin\u2019s lymphoma. Cancer Pract 6:195\u2013197","journal-title":"Cancer Pract"},{"key":"99_CR4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<247::AID-AJH9>3.0.CO;2-T","volume":"62","author":"H Yang","year":"1999","unstructured":"Yang H, Rosove MH, Figlin RA (1999) Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia. Am J Hematol 62:247\u2013250","journal-title":"Am J Hematol"},{"key":"99_CR5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s002770050419","volume":"77","author":"M Jensen","year":"1998","unstructured":"Jensen M, Winkler U, Manzke O, Diehl V, Engert A (1998) Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 77:89\u201391","journal-title":"Ann Hematol"},{"key":"99_CR6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.thj.6200244","volume":"4","author":"Y Abou Mourad","year":"2003","unstructured":"Abou Mourad Y, Taher A, Shamseddine A (2003) Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20. Hematol J 4:222\u2013224","journal-title":"Hematol J"},{"key":"99_CR7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1532\/IJH97.NA0504","volume":"82","author":"FI Jabr","year":"2005","unstructured":"Jabr FI (2005) Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma. Int J Hematol 82:312\u2013314","journal-title":"Int J Hematol"},{"key":"99_CR8","first-page":"488","volume":"49","author":"RC Chasty","year":"1993","unstructured":"Chasty RC, Liu-Yin JA (1993) Acute tumour lysis syndrome. Br J Hosp Med 49:488\u2013492","journal-title":"Br J Hosp Med"},{"key":"99_CR9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/10428190290021452","volume":"43","author":"R Lerza","year":"2002","unstructured":"Lerza R, Botta M, Barsotti B, et al (2002) Dexamethazone-induced acute tumor lysis syndrome in a T-cell malignant lymphoma. Leuk Lymphoma 43:1129\u20131132","journal-title":"Leuk Lymphoma"},{"key":"99_CR10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/(SICI)1096-8652(199701)54:1<85::AID-AJH15>3.0.CO;2-9","volume":"54","author":"AK Coutinho","year":"1997","unstructured":"Coutinho AK, de O Santos M, Pinczowski H, Feher O, del Giglio A (1997) Tumor lysis syndrome in a case of chronic lymphocytic leukemia induced by high-dose corticosteroids. Am J Hematol 54:85\u201386","journal-title":"Am J Hematol"},{"key":"99_CR11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00007611-199403000-00024","volume":"87","author":"IA Malik","year":"1994","unstructured":"Malik IA, Abubakar S, Alam F, Khan A (1994) Dexamethasone-induced tumor lysis syndrome in high-grade non-Hodgkin\u2019s lymphoma. South Med J 87:409\u2013411","journal-title":"South Med J"},{"key":"99_CR12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.amjmed.2003.09.045","volume":"116","author":"MB Davidson","year":"2004","unstructured":"Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116:546\u2013554","journal-title":"Am J Med"},{"key":"99_CR13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","volume":"127","author":"MS Cairo","year":"2004","unstructured":"Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3\u201311","journal-title":"Br J Haematol"},{"key":"99_CR14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.2830470212","volume":"47","author":"AM Jasek","year":"1994","unstructured":"Jasek AM, Day HJ (1994) Acute spontaneous tumor lysis syndrome. Am J Hematol 47:129\u2013131","journal-title":"Am J Hematol"},{"key":"99_CR15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0093-7754(03)00239-2","volume":"30","author":"TS Lin","year":"2003","unstructured":"Lin TS, Lucas MS, Byrd JC (2003) Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol 30:483\u2013492","journal-title":"Semin Oncol"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-008-0099-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-008-0099-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-008-0099-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T17:21:27Z","timestamp":1559409687000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-008-0099-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,13]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["99"],"URL":"https:\/\/doi.org\/10.1007\/s11739-008-0099-1","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,13]]}}}